"GLP-1" has become a category label for things that aren't GLP-1 agonists
Small terminology gripe that causes real confusion.
GLP-1 agonist means an agonist at the GLP-1 receptor. Semaglutide is one.
Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple. Calling those "GLP-1s" is like calling every antibiotic penicillin.
It matters because the differences between them are precisely the receptor differences, so a label that erases those differences makes the comparisons incoherent.
I don't expect to win this one — the usage is entrenched. But if you're reading a summary that calls everything a GLP-1, that's a decent signal about how carefully the rest was written.